Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: TDOC.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Teladoc Health (TDOC) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$7.58

+20.2%

2031

5-Year

BUY

$13

+102.5%

Published batch insight

Virtual Care Pioneer Navigates Looming Convertible Debt Wall Amid Chronic Margin Inflection

Analyses reveal sharp divergence regarding normalized free cash flow durability, yet high consensus that core enterprise integrated care provides essential operational ballast. While direct-to-consumer therapy suffers ongoing attrition, substantial balance-sheet liquidity and expanding commercial payer reimbursements buffer upcoming convertible debt maturities against immediate insolvency risks.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

J.P. Morgan (Titan), Sherlock Holmes (Whistleblower), Michael Burry (Vulture), Universal Investor (Polymath), Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Elon Musk (Visionary), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Teladoc Health at the forecast anchor (2026-09-18): $20,248 in five years versus $13,892 for S&P 500 benchmark.

Teladoc Health · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Teladoc Health compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 6.3 USD1-year price return: +20.25%5-year price return: +102.48%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	6.33	+0.53%	+0.53%	Third-quarter results reflect persistent consumer therapy contraction and seasonal digital ad inflation. Year-end tax-loss selling and looming convertible debt maturities keep sentiment depressed, though positive underlying operating cash flow prevents further structural breakdown.
Q1 2027	6.66	+5.12%	+5.67%	Full-year reporting and forward guidance clarify the commercial insurance transition at BetterHelp. Management outlines an executable framework utilizing liquid cash reserves to address upcoming convertible debt, initiating modest multiple stabilization from distressed levels.
Q2 2027	7.21	+8.26%	+14.40%	The June convertible maturity dominates market dynamics. Cash settlement and modest replacement credit lines neutralize immediate solvency risk without common equity dilution, triggering sharp institutional short-covering despite temporary liquidity drawdowns.
Q3 2027	7.58	+5.11%	+20.25%	Post-refinancing clarity establishes a renewed fundamental baseline. Higher interest expense on replacement debt tempers enthusiasm, but expanding chronic care enrollment and initial commercial insurance reimbursement gains support sequential operational stabilization.
Q4 2027	7.96	+5.12%	+26.40%	Autumn employer health plan selling season confirms solid enterprise retention across Fortune 500 accounts. Narrowing net losses and reduced stock-based compensation demonstrate sustained overhead discipline, supporting gradual multiple recovery into year-end.
Q1 2028	8.37	+5.05%	+32.79%	Full-year 2027 financials demonstrate adjusted EBITDA resilience and positive post-software free cash flow. As solvency fears recede permanently, fundamental value investors re-rate the business toward historical healthcare IT utility multiples.
Q2 2028	8.77	+4.79%	+39.16%	BetterHelp commercial insurance sessions scale, partially offsetting legacy cash-pay attrition. Ambient clinical documentation tools lower provider administrative burdens, expanding gross margins toward seventy percent and confirming operational turnaround feasibility.
Q3 2028	8.92	+1.78%	+41.64%	Mid-year consultation seasonality and competitive pricing pressure from captive payer telehealth networks moderate top-line momentum. Underlying cash generation remains steady, allowing the balance sheet to absorb modest working-capital fluctuations without strain.
Q4 2028	9.31	+4.33%	+47.76%	Enterprise contract renewals show healthy uptake of bundled cardiometabolic and weight-management programs. Disciplined capital allocation and growing cash reserves support equity valuation, offsetting continued low-single-digit top-line drag in consumer mental health.
Q1 2029	9.69	+4.05%	+53.74%	Full-year 2028 results mark an inflection toward GAAP operating breakeven as historical acquisition amortization drops off the income statement. Eliminating accounting deficits attracts quantitative institutional screens, driving steady equity accumulation.
Q2 2029	10.04	+3.63%	+59.32%	Commercial insurance integration at BetterHelp matures, establishing predictable recurring session gross profits. Voluntary early term debt paydowns reduce annual interest burdens, directly lifting per-share cash generation and de-risking the capital structure.
Q3 2029	10.31	+2.70%	+63.62%	Summer seasonal consultation lulls prompt minor consolidation. However, entrenched provider integration across regional health plans defends high-margin recurring access fees, insulating the equity from broader macroeconomic and healthcare tech volatility.
Q4 2029	10.67	+3.47%	+69.30%	Favorable open-enrollment additions across self-insured corporate accounts deliver strong top-line visibility for the upcoming fiscal year. Expanding adjusted EBITDA margins reflect cumulative administrative efficiencies, underpinning consistent quarterly share appreciation.
Q1 2030	11.00	+3.12%	+74.58%	Full-year 2029 disclosures confirm sustained positive GAAP net income and robust free cash flow. Management evaluates shareholder-friendly capital return strategies, cementing market recognition of the company as an essential digital healthcare utility.
Q2 2030	11.20	+1.85%	+77.80%	Automated clinical triage and AI-assisted provider workflows further compress delivery overhead per consultation. Operating leverage strengthens across Integrated Care, cushioning the platform against ongoing visit-based pricing concessions demanded by national payers.
Q3 2030	11.45	+2.24%	+81.78%	Predictable operational execution across enterprise and behavioral segments maintains steady quarterly cash conversion. The equity trades in an orderly valuation channel, supported by mid-single-digit free cash flow compounding and pristine liquidity.
Q4 2030	11.85	+3.51%	+88.16%	Year-end balance-sheet deleveraging leaves net cash in a robust surplus position. Stable chronic care subscriber retention balances mature direct-to-consumer therapy dynamics, providing dependable price support during annual portfolio rebalancing cycles.
Q1 2031	12.19	+2.84%	+93.50%	Full-year 2030 earnings highlight clean operational profitability and negligible credit risk. Sell-side analysts upgrade coverage models to reflect a durable cash cow rather than a distressed speculative turnaround, sustaining upward momentum.
Q2 2031	12.47	+2.34%	+98.02%	Mature-phase execution delivers predictable clinical encounter volumes across commercial and Medicare Advantage accounts. Modest payer pricing scrutiny is fully offset by overhead discipline, maintaining stable operating margins and consistent cash flow.
Q3 2031	12.76	+2.25%	+102.48%	The five-year transformation concludes with the business valued as an indispensable, cash-generative healthcare software utility. Re-rated valuation multiples and accumulated balance-sheet cash deliver substantial cumulative recovery from trough entry levels.

The investment thesis centers on an acute mispricing between perceived insolvency and durable enterprise cash generation. While direct-to-consumer therapy revenue contracts under marketing cost inflation, the B2B Integrated Care segment delivers an entrenched, high-margin subscription annuity across one hundred million covered lives. Forensic accounting reveals that headline free cash flow is flattered by software capitalization; normalized cash generation is approximately $120 million to $140 million rather than the headline $225 million. Nevertheless, existing liquidity and positive operational cash flow fully cover the June 2027 convertible maturity without requiring dilutive equity recapitalization. Valuation sensitivity remains tied to refinancing costs and consumer stabilization.

Key insights

Capitalized software accounts for over ninety percent of capital expenditures, requiring investors to evaluate normalized cash conversion rather than flattering headline yields.
Transitioning consumer therapy toward contracted commercial insurance expands patient addressability but introduces clinician credentialing bottlenecks and bureaucratic payer revenue collection delays.
Resolving the convertible maturity removes binary distress discounts, yet higher replacement borrowing coupons permanently reduce net margins and per-share compounding velocity.

Deep Dive

Market consensus has dismissed the enterprise as an irrecoverable pandemic relic, anchored to historical goodwill write-downs and relentless revenue decay in consumer mental health. Investors widely assume that high customer acquisition costs are fatal, treating the 2027 convertible debt wall as an existential solvency threat. Consequently, prevailing sentiment prices the equity at a distressed multiple, convinced that dilutive recapitalization or operational insolvency is inevitable.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value due to an analytical blind spot that conflates consumer therapy headwinds with enterprise insolvency. The market overlooks that Integrated Care delivers resilient adjusted EBITDA margins above sixteen percent across an entrenched B2B base, while $774 million in cash and positive operational cash flow provide sufficient liquidity to retire maturing convertible notes without dilutive equity issuance. However, bulls who cite an unadjusted twenty percent free cash flow yield ignore heavy software capitalization, meaning true intrinsic undervaluation is meaningful but moderate.

Repricing catalyst

The decisive catalyst is the formal resolution of the $996.7 million convertible senior notes due June 1, 2027 through a combination of existing cash reserves and modest credit facilities. Retiring this liability without dilutive equity issuance dispels existential bankruptcy fears, compelling credit markets and institutional investors to re-evaluate the company on normalized cash earnings. The first observable confirmation will emerge via announced refinancing terms or cash tender repurchases during early 2027.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of elevated central bank interest rates and restrictive credit conditions is a distinct headwind. High benchmark yields raise prospective borrowing costs when rolling over maturing debt and compress equity valuation multiples. However, corporate employer demand for cost-saving virtual healthcare benefits provides defensive operational insulation against broader macroeconomic deceleration.

Published consensus context

Advisor disagreement

The most consequential analytical debate centers on true normalized cash generation and the ultimate fate of BetterHelp. One camp argues that reported trailing cash flow of $225 million reflects an unassailable twenty percent yield, paving the way for rapid balance-sheet de-leveraging. The opposing view demonstrates that deducting heavy capitalized software development cuts true cash flow near $130 million, while consumer churn will permanently depress top-line revenue. Reconciling this debate requires monitoring second-half 2026 cash conversion after capitalized software, alongside commercial insurance run-rates from the upcoming quarterly filings.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Enterprise Integrated Care contract stability: Integrated Care serves over one hundred million members, delivering stable revenues and adjusted EBITDA margins near 16.5%. Entrenched employer relationships and multi-condition cross-selling create substantial switching friction, defending core B2B cash flows against commoditization. This recurring enterprise earnings foundation insulates the business from retail therapy volatility and permanently finances ongoing digital health modernization. Expected impact: +32%.
Convertible note balance sheet derisking: Management possesses $774 million in cash alongside an undrawn revolving credit facility to address the $996.7 million convertible debt due June 2027. Retiring this liability through internal liquidity and modest bank facilities eliminates insolvency overhang, dramatically compressing credit default spreads and unlocking substantial equity multiple expansion from distressed historical lows. Expected impact: +28%.
BetterHelp commercial insurance network pivot: Transitioning BetterHelp from direct-to-consumer cash subscriptions toward contracted commercial insurance unlocks access to over 150 million covered lives. While initial clinician credentialing creates temporary capacity bottlenecks, in-network reimbursement lowers member acquisition costs, lengthens retention curves, and replaces volatile consumer advertising auctions with durable, recurring payer-sponsored session volume across the five-year horizon. Expected impact: +24%.
Operational overhead and compensation discipline: Executive leadership has aggressively curtailed corporate overhead and trimmed stock-based compensation by over thirty percent year-over-year. Concurrently, deploying automated intake routing and clinical documentation tools reduces clinician visit completion times. This administrative austerity closes the chasm between GAAP net loss and adjusted EBITDA, systematically enhancing operational cash flow conversion over the forecast cycle. Expected impact: +18%.

Top frictions and headwinds

Consumer therapy cash pay attrition: BetterHelp faces relentless structural headwinds as inflationary pressures squeeze discretionary household mental health budgets. Paying users fell eleven percent year-over-year as cash-pay subscribers churned, while aggressive digital advertising competition inflated acquisition costs. This persistent consumer fatigue depresses segment revenue, exerting an enduring drag on consolidated earnings until commercial insurance reimbursement achieves critical scale. Expected impact: -22%.
Replacement debt coupon step up: The 2027 convertible notes carry an ultra-low 1.25% coupon. Refinancing any residual portion in a restrictive monetary regime with policy rates near 4% will require market rates between 7% and 9%. This coupon step-up will add tens of millions in annual cash interest expense, directly compressing net income and constraining discretionary capital reinvestment. Expected impact: -18%.
Virtual care pricing commoditization pressure: Basic telehealth consultations face aggressive commoditization from regional hospital health systems, retail pharmacy clinics, and captive payer virtual networks like Optum. Health plan sponsors demand price concessions and shift contracts from fixed per-member subscription fees to utilization-based visit models. This pricing compression limits organic revenue expansion and caps long-term gross margin growth across commercial accounts. Expected impact: -15%.
Capitalized software free cash flattery: Reported free cash flow is heavily flattered by accounting conventions, as capitalized software development represents over ninety percent of total capital spending. Deducting software additions reduces true trailing cash generation from $225 million toward $130 million. Investors normalizing for recurring development expenditures will adjust cash flow yields downward, dampening potential valuation multiple expansion. Expected impact: -12%.

Tail risks

Credit freeze forced equity dilution: Dislocations across corporate credit markets coincide with operational cash deterioration ahead of the June 2027 convertible debt maturity. Unable to issue replacement credit facilities on viable terms and lacking sufficient unrestricted liquidity, management is forced into a punitive rescue financing involving deeply discounted equity-linked instruments. This restructuring would heavily dilute existing common shares, permanently crushing per-share value despite existing cash reserves holding probability below half. Probability: +22%. Expected impact: -50%.
BetterHelp regulatory and privacy penalties: Federal regulators or state attorneys general initiate sweeping enforcement actions over consumer data privacy, tracking pixels, or therapist credentialing compliance across online therapy platforms. Imposed statutory fines, mandated operational curbs, and reputational fallout would collapse user onboarding funnels and prompt commercial insurers to freeze reimbursement partnerships. While comprehensive compliance remediation keeps probability below fifty percent, materialization would decimate behavioral health cash generation and trigger major impairments. Probability: +20%. Expected impact: -45%.

Tail opportunities

Strategic private equity buyout bid: A private equity consortium or commercial payer launches an unsolicited takeover bid, capitalizing on depressed valuations near 0.5 times sales and predictable B2B cash flows. A buyer could carve out BetterHelp and optimize Integrated Care away from public scrutiny. The event remains below fifty percent probability due to antitrust scrutiny, but would command a substantial control premium. Probability: +28%. Expected impact: +65%.
Commercial GLP1 companion program breakthrough: Commercial payers mandate digital lifestyle and clinical companion programs for reimbursed anti-obesity and cardiometabolic medications starting in 2027. Leveraging its established chronic condition architecture, the enterprise captures preferred vendor status across national employer coalitions. This catalytic alignment injects hundreds of thousands of high-margin subscriptions into Integrated Care, accelerating organic revenue into double digits. Probability remains below fifty percent because payers frequently evaluate internal disease management alternatives. Probability: +25%. Expected impact: +55%.

What to monitor

Thesis watchpoints

-- Confirmation: BetterHelp commercial insurance run-rate exceeding $125 million annualized by Q4 2026 confirms viable payer substitution for lost cash-pay revenue.

Key insights

Deterioration: Post-software normalized free cash flow falling below $100 million annualized across 2027 signals working-capital strain and refinancing vulnerability.
Reassessment: Refinancing terms on the June 2027 convertible debt requiring interest coupons above 9.5% or material equity warrant dilution.

Company Financial Analysis

Teladoc Health Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Reported financial results present a striking contrast between headline accounting deficits and resilient operational cash production. For fiscal 2025, revenue contracted slightly to $2.53 billion, while reported net losses narrowed dramatically to $200 million as massive historical goodwill write-offs ended. Second-quarter 2026 revenue of $607 million reflected continued contraction in consumer therapy, but enterprise healthcare services held steady. Crucially, headline accounting losses are driven by non-cash amortization from past acquisitions rather than ongoing cash burn. The core business generated $225 million in trailing cash flow, though factoring in internal software spending lowers true underlying cash generation closer to $130 million. This cash cushion stabilizes the company while management reshapes operations.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 2.5B	USD -200.3M	USD 285.5M
2024	USD 2.6B	USD -1B	USD 282.9M
2023	USD 2.6B	USD -220.4M	USD 193.7M
2022	USD 2.4B	USD -13.7B	USD 172.8M
2021	USD 2B	USD -428.8M	USD 185.5M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	--	TTM	Loss-making	USD / USD
2024	--	TTM	Loss-making	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	--	Annual	Loss-making	USD / USD
2021	--	Annual	Loss-making	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability metrics reveal a dramatic split between operating units. Consolidated gross margins remain structurally high near 70%, proving that core virtual clinical consultations retain attractive underlying economics. However, operating margins diverged sharply in the second quarter of 2026: Integrated Care maintained a solid 16.5% adjusted EBITDA margin, while consumer-focused BetterHelp fell to breakeven at 0.2%. This divergence stems from inflated advertising costs in direct-to-consumer therapy, which management addressed by reducing marketing spend. Shifting therapy into in-network commercial insurance reduces member acquisition costs. As non-cash acquisition amortization rolls off and cost discipline takes hold, consolidated operating profitability is positioned to rebound gradually.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD -263M	-10.4%	-7.9%
2024	USD -1B	-39.7%	-39.0%
2023	USD -248.6M	-9.6%	-8.5%
2022	USD -13.2B	-548.4%	-567.5%
2021	USD -265.6M	-13.1%	-21.1%

Balance sheet and leverage

AI Review

The balance sheet presents a sharp contrast between substantial liquid resources and an impending debt maturity. Teladoc held $774 million in cash equivalents at the end of June 2026 against $996.7 million in convertible senior notes maturing in June 2027. An undrawn $300 million credit facility provides total gross liquidity exceeding $1.07 billion. This ample liquidity disproves widespread market fears of imminent bankruptcy. Management has adequate capacity to retire the notes using accumulated cash and conservative bank loans without diluting shareholders. However, repaying the debt will reduce cash balances and raise interest expenses on replacement borrowing, making ongoing operational cash generation essential.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 1B	USD 781.1M	USD 259.1M net debt	2.69x
2024	USD 1.6B	USD 1.3B	USD 286.3M net debt	1.77x
2023	USD 1.6B	USD 1.1B	USD 468.6M net debt	3.54x
2022	USD 1.6B	USD 918.2M	USD 668.7M net debt	3.22x
2021	USD 1.3B	USD 896M	USD 386.7M net debt	3.70x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Physical capital expenditure appears almost nonexistent, with traditional equipment purchases absorbing only 0.35% of revenue in 2025 and just $2.6 million during the first half of 2026. This reflects a virtual delivery model that requires minimal brick-and-mortar investment compared to physical hospital networks. However, real capital intensity is concentrated in software development, which consumed $62.2 million during the first half of 2026. Management has redirected investment away from aggressive consumer marketing toward platform automation and clinical intelligence tools. This software discipline protects near-term cash reserves ahead of upcoming bond maturities, though continuing technology spending remains essential to prevent platform obsolescence against rivals.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 8.9M	USD 277.9M
2024	USD 10.8M	USD 307.3M
2023	USD 156.3M	USD 348.5M
2022	USD 16.5M	USD 333.6M
2021	USD 8.5M	USD 311.9M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	209	+25.8%	Not available	ORIGINAL
5Y	BUY	175	+123%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	5.8	6.45	6.8	14
+6M	March 18, 2027	5.45	6.87	8.03	14
+9M	June 18, 2027	5.61	7.54	9.23	14
+1Y	September 18, 2027	5.95	7.93	10.16	14
+15M	December 18, 2027	6.19	8.34	10.97	14
+18M	March 18, 2028	6.5	8.79	11.63	14
+21M	June 18, 2028	6.69	9.26	12.44	14
+2Y	September 18, 2028	6.57	9.54	13.06	14
+27M	December 18, 2028	6.9	9.98	13.85	14
+30M	March 18, 2029	7.18	10.41	14.4	14
+33M	June 18, 2029	7.46	10.82	15.12	14
+3Y	September 18, 2029	7.68	11.11	15.57	14
+39M	December 18, 2029	7.83	11.52	16.2	14
+42M	March 18, 2030	7.99	11.94	16.85	14
+45M	June 18, 2030	7.83	12.3	17.35	14
+4Y	September 18, 2030	8.14	12.55	17.87	14
+51M	December 18, 2030	8.46	13.01	18.85	14
+54M	March 18, 2031	8.56	13.43	19.79	14
+57M	June 18, 2031	8.3	13.75	20.58	14
+5Y	September 18, 2031	8.47	14.05	21.2	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

Independent assessments converge on a critical operational dichotomy: durable enterprise Integrated Care subscription cash flows contrast with sharp consumer therapy revenue decay. Most perspectives acknowledge that existing balance-sheet liquidity and undrawn credit capacity provide sufficient runway to resolve the impending 2027 convertible debt maturity. However, relative weighting heavily rewards analyses that rigorously adjust free cash flow for aggressive software capitalization and executive stock compensation rather than uncritically accepting headline trailing cash metrics. The strongest contrarian case cautions that higher replacement borrowing coupons in a restrictive monetary regime will permanently compress equity earnings once low-coupon debt matures. Conversely, unverified assumptions regarding imminent bankruptcy or effortless multiple expansion to pre-pandemic peaks are systematically downweighted. Relative allocations prioritize forensic scrutiny of working capital and debt rollover mechanics over speculative takeover narratives.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight16.4/100

Weighted highest alongside the primary polymath report for exceptional evidentiary rigor, reconstructing normalized free cash flow by expensing capitalized software, modeling equity dilution, and establishing a grounded, realistic valuation framework.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight16.4/100

Receives superior weighting due to forensic examination of software capitalization flattery, realistic normalization of free cash flow, and detailed segmentation between high-margin Integrated Care and deteriorating direct-to-consumer therapy ahead of the critical 2027 debt maturity.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight9.1/100

Merits substantial weighting for rigorous segment EBITDA decomposition, realistic appraisal of commercial insurance transition timelines, and disciplined balance-sheet tracking that demonstrates non-dilutive debt retirement capability from internal liquidity.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight9.1/100

Merits significant allocation for disciplined balance-sheet forensics, accurate appraisal of convertible debt redemption capacity using existing cash, and clear identification of therapist recruitment bottlenecks in behavioral health.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight7.3/100

Supported by solid forensic tracking of commercial in-network coverage expansion, administrative overhead cuts, and executable debt retirement steps, providing strong evidence-based causal links between operational stabilization and multiple recovery.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight7.3/100

Merits high weighting for incisive appraisal of regulatory telehealth extension dynamics, payer insourcing frictions, and detailed mechanics of replacement financing costs in a restrictive central bank monetary regime.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight4.5/100

Assigned moderate weight for sound identification of core enterprise switching costs and balance-sheet liquidity, though limited by uncritical reliance on headline trailing cash flow without adjusting for heavy historical capitalized software development outlays.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight4.5/100

Receives balanced weighting for valuable analysis of executive payer restructuring and chronic care cross-selling dynamics, but downweighted for overly optimistic multiple expansion assumptions in an elevated interest rate environment.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight4.5/100

Weighted moderately for a pragmatic assessment of enterprise healthcare inertia and aggressive overhead pruning, though discounted for treating clinical software commoditization and competitive AI threats with insufficient balance-sheet depth.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight4.5/100

Assigned moderate weight for coherent analysis of multi-condition bundling and commercial payer expansion, though constrained by optimistic multiple normalization targets that overlook prospective replacement debt coupon step-ups.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.5/100

Receives balanced allocation for recognizing the enterprise cash-harvesting turnaround and downside book value protections, tempered by somewhat generic treatments of AI clinical disintermediation and stock-based compensation dilution.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight4.5/100

Weighted moderately for robust macroeconomic contextualization and enterprise chronic care stickiness analysis, but tempered by aggressive price-to-sales multiple targets that exceed historical post-bubble medtech reorganization standards.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.5/100

Receives balanced weighting for detailed examination of provider credentialing bottlenecks and visit-based contract transitions, balanced against an aggressive projection of terminal valuation multiple recovery that slightly understates long-term competitive payer insourcing.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight2.7/100

Assigned lower weight due to substantial reliance on unadjusted headline cash flow figures and repeated debt-buyback assumptions, though credited for recognizing enterprise contract switching costs and short-term liquidity cushions.

Skip to references

Research Provenance

References & Context

This Teladoc Health consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 52 deduplicated sources retained for this batch.

01Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
020001477449 false 0001477449 2020-05-18 2020-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:sharessec.gov
03Secsec.gov
04tdoc-20251231sec.gov
05tdoc-20260630sec.gov
06Teladoc Health, Inc. - Form 10-Q - FY2026sec.gov
07Teladoc Health, Inc. - Teladoc Health Reports Second Quarter 2026 Resultsir.teladochealth.com
08Dealroom.co | BetterHelp president sells entire $71K Teladoc stake, exits position completelyapp.dealroom.co
09Let's Buy BetterHelpbeyondbillions.substack.com
10TDOC Stock Quote Price and Forecast | CNNcnn.com
11Teladoc Health CEO lays out telehealth giant's M&A strategy following first year at the helmfiercehealthcare.com
12Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path? (TDOC)finance.yahoo.com
13Teladoc Health Q2 Earnings Call Highlightsfinance.yahoo.com
14Teladoc Health, Inc. Q2 2026 Earnings Call Summaryfinance.yahoo.com
15Teladoc Q2 2026 slides: revenue miss drives sharp stock decline By Investing.cominvesting.com

And 37 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.